Systemic administration of HMG-CoA reductase inhibitor protects the blood–retinal barrier and ameliorates retinal inflammation in type 2 diabetes

Experimental Eye Research ◽

10.1016/j.exer.2009.02.013 ◽

2009 ◽

Vol 89 (1) ◽

pp. 71-78 ◽

Author(s):

Jingming Li ◽

Joshua J. Wang ◽

Danyang Chen ◽

Robert Mott ◽

Qiang Yu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Reductase Inhibitor ◽

Systemic Administration ◽

Blood Retinal Barrier ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Retinal Inflammation ◽

Download Full-text

The HMG-CoA Reductase Inhibitor Cerivastatin Lowers Advanced Glycation End Products in Patients with Type 2 Diabetes

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-2007-973830 ◽

2007 ◽

Vol 115 (06) ◽

pp. 372-375 ◽

Author(s):

H. Scharnagl ◽

T. Stojakovic ◽

K. Winkler ◽

S. Rosinger ◽

W. März ◽

...

Keyword(s):

Type 2 Diabetes ◽

Advanced Glycation End Products ◽

Reductase Inhibitor ◽

Advanced Glycation ◽

Hmg Coa Reductase ◽

Glycation End Products ◽

End Products ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text

Efficacy of Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes

Diabetes Care ◽

10.2337/diacare.28.12.2980-a ◽

2005 ◽

Vol 28 (12) ◽

pp. 2980-2981 ◽

Author(s):

T. Kawai ◽

M. Tokui ◽

O. Funae ◽

S. Meguro ◽

S. Yamada ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glucose Metabolism ◽

Reductase Inhibitor ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text

HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

Life Sciences ◽

10.1016/s0024-3205(02)02038-6 ◽

2002 ◽

Vol 71 (20) ◽

pp. 2403-2412 ◽

Author(s):

Hirohito Sone ◽

Akimitsu Takahashi ◽

Hitoshi Shimano ◽

Shun Ishibashi ◽

Gen Yoshino ◽

...

Keyword(s):

Type 2 Diabetes ◽

Reductase Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text

Intense Cholesterol Lowering Therapy with a HMG-CoA Reductase Inhibitor does not Improve Nitric Oxide Dependent Endothelial Function in Type-2-Diabetes

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-2005-865642 ◽

2005 ◽

Vol 113 (06) ◽

pp. 324-330 ◽

Author(s):

B. Balletshofer ◽

S. Goebbel ◽

K. Rittig ◽

M. Enderle ◽

I. Schmölzer ◽

...

Keyword(s):

Nitric Oxide ◽

Type 2 Diabetes ◽

Endothelial Function ◽

Reductase Inhibitor ◽

Cholesterol Lowering ◽

Hmg Coa Reductase ◽

Lowering Therapy ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text

HMG-CoA Reductase Inhibitor, Simvastatin Improves Reverse Cholesterol Transport in Type 2 Diabetic Patients with Hyperlipidemia

Journal of Atherosclerosis and Thrombosis ◽

10.5551/jat.e512 ◽

2008 ◽

Vol 15 (1) ◽

pp. 20-25 ◽

Author(s):

Jing-Zhi Guan ◽

Naoki Tamasawa ◽

Hiroshi Murakami ◽

Jun Matsui ◽

Jutaro Tanabe ◽

...

Keyword(s):

Reverse Cholesterol Transport ◽

Reductase Inhibitor ◽

Diabetic Patients ◽

Cholesterol Transport ◽

Type 2 Diabetic Patients ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Coa Reductase ◽

Type 2 Diabetic

Download Full-text

Clinical effects of HMG-CoA reductase inhibitor on carotid plaque lesions in Japanese type 2 diabetic patients

Diabetes Research and Clinical Practice ◽

10.1016/s0168-8227(00)81075-x ◽

2000 ◽

Vol 50 ◽

pp. 315

Author(s):

M Ohashi ◽

M Nomura ◽

K Ichida ◽

K Tukurimichi ◽

J Tanouchi ◽

...

Keyword(s):

Carotid Plaque ◽

Reductase Inhibitor ◽

Diabetic Patients ◽

Clinical Effects ◽

Type 2 Diabetic Patients ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Coa Reductase ◽

Type 2 Diabetic

Download Full-text

Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells

Oncology Reports ◽

10.3892/or.11.5.1053 ◽

2004 ◽

Author(s):

Takemi Otsuki ◽

Haruko Sakaguchi ◽

Tamayo Hatayama ◽

Tomohiro Fujii ◽

Takayuki Tsujioka ◽

...

Keyword(s):

Reductase Inhibitor ◽

Hmg Coa Reductase ◽

Myeloma Cells ◽

Hmg Coa Reductase Inhibitor ◽

Coa Reductase ◽

Human Myeloma Cells

Download Full-text

HMG-COA REDUCTASE INHIBITOR AFFECTS BLOOD PRESSURE AND VASCULAR REACTIVITY

Clinical and Experimental Pharmacology and Physiology ◽

10.1111/j.1440-1681.1995.tb02934.x ◽

1995 ◽

Vol 22 (s1) ◽

pp. S316-S317 ◽

Author(s):

N. Li ◽

M. Sawamura ◽

Y. Nara ◽

K. Kizawa ◽

K. Ikeda ◽

...

Keyword(s):

Blood Pressure ◽

Reductase Inhibitor ◽

Vascular Reactivity ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text

Combined treatment of angiotensin receptor blocker and HMG-CoA reductase inhibitor synergistically improves cardiac dysfunction in Dahl rats

Journal of Molecular and Cellular Cardiology ◽

10.1016/j.yjmcc.2007.07.050 ◽

2008 ◽

Vol 44 (2) ◽

pp. 446-447

Author(s):

Yasuhiro Maejima ◽

Susumu Adachi ◽

Kazuya Isobe ◽

Hiroshi Ito ◽

Mitsuaki Isobe

Keyword(s):

Cardiac Dysfunction ◽

Reductase Inhibitor ◽

Angiotensin Receptor Blocker ◽

Combined Treatment ◽

Receptor Blocker ◽

Angiotensin Receptor ◽

Hmg Coa Reductase ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

Atherosclerosis ◽

10.1016/s0021-9150(01)00765-1 ◽

2002 ◽

Vol 163 (1) ◽

pp. 157-164 ◽

Author(s):

Yoshihiro Noji ◽

Toshinori Higashikata ◽

Akihiro Inazu ◽

Atsushi Nohara ◽

Kosei Ueda ◽

...

Keyword(s):

Familial Hypercholesterolemia ◽

Reductase Inhibitor ◽

Term Treatment ◽

Hmg Coa Reductase ◽

Heterozygous Familial Hypercholesterolemia ◽

Long Term Treatment ◽

Hmg Coa Reductase Inhibitor ◽

Download Full-text